SomaLogic is featured prominently in a press release announcing the first patient enrollment in a diabetes prevention study at the Leeds Centre for Personalised Medicine and Health in the UK.
SomaLogic, Inc., announced today that its new Chief Executive Officer, Roy Smythe, M.D., will present the company’s current status and strategic direction at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California. Dr. Smythe’s presentation, which is included in the Conference’s “Emerging Markets Track,” is scheduled for Wednesday, January 9, 2019 at 3:00 p.m. Pacific Time.
deCODE genetics, an Amgen subsidiary, and SomaLogic announce collaboration to perform large-scale protein analysis of up to 40,000 human samples
deCODE genetics, an Amgen subsidiary, and SomaLogic, Inc. today announced a collaboration that brings together SomaLogic’s expertise in human proteins with deCODE’s expertise in human genetics. The collaboration combines deCODE’s rich data sets with SomaLogic’s leading protein measurement capabilities to enhance the understanding of how human disease and health are mediated through proteins to influence health outcomes.
A story published online today in The New York Times Magazine features SomaLogic and describes how measuring thousands of blood proteins could impact diagnostic testing and health screening.
The SomaLogic Board of Directors announced today that they have selected Roy Smythe, M.D. as the next Chief Executive Officer of SomaLogic. A trained surgeon and former translational scientist, Dr. Smythe joins SomaLogic from Royal Philips, where he served as Chief Medical Officer for Strategy and Partnerships.
Larry Gold, the founder and chairman of the board of SomaLogic, has been awarded the 8th International Steven Hoogendijk Prize by the Dutch Batavian Society of Experimental Philosophy. The biennial Hoogendijk prize honors global breakthroughs at the cutting edge of medicine and technology.
An article published online today in Nature Methods describes the use of SOMAmer® reagents to specifically label and precisely visualize single molecules within single cells. This new use for SOMAmer reagents opens the door to viewing how biological structures are organized on a molecular scale and how they function in living tissue in real time.
Integrated protein “communications” networks link genetic variations to complex aging-related diseases
Addressing one of the largest remaining knowledge gaps in biomedical science, researchers from Novartis, SomaLogic, and the Icelandic Heart Association have found a way to tie genetic variations to complex disorders, such as heart disease and diabetes. Their findings, published online today in the journal Science, demonstrate that communication between networks of proteins can explain the connections between genes and diseases.
SomaLogic licenses GNS Healthcare’s REFS™ technology for analysis of its SOMAscan®-derived proteomic data
SomaLogic and GNS Healthcare announced today that SomaLogic has obtained a license to apply GNS Healthcare’s proprietary REFS™ (Reverse Engineering & Forward Simulation) causal machine learning technology to SomaLogic’s proprietary SOMAscan®-derived protein data sets.
An article published today in the journal Nature brings us closer to understanding how differences in the genomes of individuals help contribute to common diseases and influence disease risk. Specifically, this study – by far the largest of its kind to date – revealed the effects of genetic variations on the levels of circulating blood proteins across thousands of individuals.